Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA)

Jwan Khal, Michael J. Tisdale

Research output: Contribution to journalArticlepeer-review


Eicosapentaenoic acid (EPA) has been shown to attenuate muscle atrophy in cancer, starvation and hyperthermia by downregulating the increased expression of the ubiquitin-proteasome proteolytic pathway leading to a reduction in protein degradation. In the current study EPA (0.5 g/kg) administered to septic mice completely attenuated the increased protein degradation in skeletal muscle by preventing the increase in both gene expression and protein concentration of the alpha- and beta-subunits of the 20S proteasome, as well as functional activity of the proteasome, as measured by the 'chymotrypsin-like' enzyme activity. These results suggest that muscle protein catabolism in sepsis is mediated by the same intracellular signalling pathways as found in other catabolic conditions.
Original languageEnglish
Pages (from-to)238-240
Number of pages3
JournalBiochemical and Biophysical Research Communications
Issue number2
Early online date12 Aug 2008
Publication statusPublished - 17 Oct 2008


  • sepsis
  • muscle atrophy
  • EPA
  • ubiquitin-proteasome proteolysis


Dive into the research topics of 'Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA)'. Together they form a unique fingerprint.

Cite this